vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
UNITED SECURITY BANCSHARES is the larger business by last-quarter revenue ($13.5M vs $9.1M, roughly 1.5× Protalix BioTherapeutics, Inc.). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs -60.3%, a 85.5% gap on every dollar of revenue. On growth, UNITED SECURITY BANCSHARES posted the faster year-over-year revenue change (13.6% vs -49.9%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $1.6M). Over the past eight quarters, UNITED SECURITY BANCSHARES's revenue compounded faster (3.0% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
PLX vs UBFO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $13.5M |
| Net Profit | $-5.5M | $3.4M |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | 31.5% |
| Net Margin | -60.3% | 25.2% |
| Revenue YoY | -49.9% | 13.6% |
| Net Profit YoY | -184.8% | 36.8% |
| EPS (diluted) | $-0.06 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $13.5M | ||
| Q3 25 | $17.9M | $14.0M | ||
| Q2 25 | $15.7M | $12.6M | ||
| Q1 25 | $10.1M | $13.7M | ||
| Q4 24 | $18.2M | $11.9M | ||
| Q3 24 | $18.0M | $13.8M | ||
| Q2 24 | $13.5M | $13.0M | ||
| Q1 24 | — | $12.8M |
| Q4 25 | $-5.5M | $3.4M | ||
| Q3 25 | $2.4M | $4.0M | ||
| Q2 25 | $164.0K | $2.2M | ||
| Q1 25 | $-3.6M | $2.7M | ||
| Q4 24 | $6.5M | $2.5M | ||
| Q3 24 | $3.2M | $3.8M | ||
| Q2 24 | $-2.2M | $4.3M | ||
| Q1 24 | — | $4.2M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | 31.5% | ||
| Q3 25 | 11.9% | 40.3% | ||
| Q2 25 | 7.5% | 24.0% | ||
| Q1 25 | -41.0% | 27.5% | ||
| Q4 24 | 39.6% | 27.5% | ||
| Q3 24 | 22.2% | 37.1% | ||
| Q2 24 | -18.0% | 46.4% | ||
| Q1 24 | — | 45.9% |
| Q4 25 | -60.3% | 25.2% | ||
| Q3 25 | 13.2% | 28.7% | ||
| Q2 25 | 1.0% | 17.2% | ||
| Q1 25 | -35.8% | 19.6% | ||
| Q4 24 | 35.6% | 20.9% | ||
| Q3 24 | 18.0% | 27.7% | ||
| Q2 24 | -16.4% | 33.0% | ||
| Q1 24 | — | 32.6% |
| Q4 25 | $-0.06 | $0.18 | ||
| Q3 25 | $0.03 | $0.23 | ||
| Q2 25 | $0.00 | $0.13 | ||
| Q1 25 | $-0.05 | $0.16 | ||
| Q4 24 | $0.10 | $0.14 | ||
| Q3 24 | $0.03 | $0.22 | ||
| Q2 24 | $-0.03 | $0.25 | ||
| Q1 24 | — | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $139.7M |
| Total Assets | $82.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $264.2M | ||
| Q3 25 | $13.6M | $211.1M | ||
| Q2 25 | $17.9M | $199.5M | ||
| Q1 25 | $19.5M | $198.4M | ||
| Q4 24 | $19.8M | $216.9M | ||
| Q3 24 | $27.4M | $216.8M | ||
| Q2 24 | $23.4M | $166.3M | ||
| Q1 24 | — | $168.6M |
| Q4 25 | $48.2M | $139.7M | ||
| Q3 25 | $52.9M | $137.4M | ||
| Q2 25 | $49.9M | $134.3M | ||
| Q1 25 | $45.2M | $132.9M | ||
| Q4 24 | $43.2M | $130.4M | ||
| Q3 24 | $32.4M | $132.9M | ||
| Q2 24 | $28.6M | $127.3M | ||
| Q1 24 | — | $124.2M |
| Q4 25 | $82.3M | $1.2B | ||
| Q3 25 | $82.3M | $1.2B | ||
| Q2 25 | $78.5M | $1.2B | ||
| Q1 25 | $73.9M | $1.2B | ||
| Q4 24 | $73.4M | $1.2B | ||
| Q3 24 | $61.6M | $1.3B | ||
| Q2 24 | $91.5M | $1.2B | ||
| Q1 24 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $22.1M |
| Free Cash FlowOCF − Capex | $1.6M | $19.8M |
| FCF MarginFCF / Revenue | 17.8% | 146.0% |
| Capex IntensityCapex / Revenue | 4.4% | 16.8% |
| Cash ConversionOCF / Net Profit | — | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $22.1M | ||
| Q3 25 | $-3.7M | $7.0M | ||
| Q2 25 | $-5.2M | $8.7M | ||
| Q1 25 | $-5.1M | $3.0M | ||
| Q4 24 | $4.0M | $19.6M | ||
| Q3 24 | $4.1M | $5.4M | ||
| Q2 24 | $-3.6M | $2.3M | ||
| Q1 24 | — | $7.4M |
| Q4 25 | $1.6M | $19.8M | ||
| Q3 25 | $-4.2M | $6.1M | ||
| Q2 25 | $-5.7M | $8.1M | ||
| Q1 25 | $-5.4M | $2.9M | ||
| Q4 24 | $3.6M | $18.6M | ||
| Q3 24 | $4.0M | $5.3M | ||
| Q2 24 | $-3.8M | $2.0M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | 17.8% | 146.0% | ||
| Q3 25 | -23.7% | 43.7% | ||
| Q2 25 | -36.2% | 64.3% | ||
| Q1 25 | -53.0% | 21.2% | ||
| Q4 24 | 19.6% | 156.0% | ||
| Q3 24 | 22.4% | 38.1% | ||
| Q2 24 | -28.1% | 15.5% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | 4.4% | 16.8% | ||
| Q3 25 | 2.8% | 6.0% | ||
| Q2 25 | 2.8% | 4.6% | ||
| Q1 25 | 3.0% | 0.9% | ||
| Q4 24 | 2.3% | 8.7% | ||
| Q3 24 | 0.5% | 0.7% | ||
| Q2 24 | 1.3% | 2.2% | ||
| Q1 24 | — | 3.6% |
| Q4 25 | — | 6.46× | ||
| Q3 25 | -1.58× | 1.73× | ||
| Q2 25 | -31.91× | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | 0.61× | 7.87× | ||
| Q3 24 | 1.27× | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
UBFO
Segment breakdown not available.
